The therapeutic landscape of metastatic clear cell renal cell carcinoma (ccRCC) has rapidly expanded, and there is an urgent need to develop non-invasive biomarkers that can select an optimal therapy or evaluate the response in real time.
The therapeutic landscape of metastatic clear cell renal cell carcinoma (ccRCC) has rapidly expanded, and there is an urgent need to develop non-invasive biomarkers that can select an optimal therapy or evaluate the response in real time.